This article has been updated to correct the name of Clinical Genomics' ctDNA methylation test. It is Colvera, not ColoVantage.

NEW YORK (GenomeWeb) – Clinical Genomics has published a study demonstrating that its epigenetics-based ctDNA test picks up twice the number of colorectal cancer recurrences as currently used blood tests for carcinoembryonic antigen (CEA).

The study was published online this month in Cancer Medicine and will also appear in the journal's October print issue.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.